The Biotechnology Institute, of Arlington, Va., appointed Scott May vice president for systems and curriculum.
Trubion Pharmaceuticals Inc., of Seattle, appointed Michelle Burris senior vice president and chief financial officer.
U.S. BioDefense Inc., of City of Industry, Calif., retained Martha Farmer as consultant for technical communications of its current initiatives.
Vasogen Inc., of Toronto, appointed Ronald Cresswell and Calvin Stiller to its board.
Verus Pharmaceuticals Inc., of San Diego, appointed Ahmet Tutuncu vice president, medical affairs.
Vion Pharmaceuticals Inc., of New Haven, Conn., appointed Meghan Fitzgerald chief business officer.
ViroPharma Inc., of Exton, Pa., appointed John Leone to its board and named Vincent Milano chief operating officer; Clayton Fletcher vice president, business development; Thomas Lembck vice president, information technology; Stephen Villano vice president, clinical research and development; and Debra Gayda vice president, regulatory affairs.
Voyager Pharmaceutical Corp., of Raleigh, N.C., appointed Joseph DeVeaugh-Geiss interim chief medical officer.
XOMA Ltd., of Berkeley, Calif., appointed Robert Gundel vice president, scientific corporate development; Mary Haak-Frendscho vice president, preclinical research and development; Mark White vice president, cell and analytical development; and Paul Goodson senior director, investor relations.
York Pharma, of Hitchin, UK, appointed Allan Salem to its board.